JP2023512763A5 - - Google Patents

Info

Publication number
JP2023512763A5
JP2023512763A5 JP2022547697A JP2022547697A JP2023512763A5 JP 2023512763 A5 JP2023512763 A5 JP 2023512763A5 JP 2022547697 A JP2022547697 A JP 2022547697A JP 2022547697 A JP2022547697 A JP 2022547697A JP 2023512763 A5 JP2023512763 A5 JP 2023512763A5
Authority
JP
Japan
Prior art keywords
item
crystalline form
anhydrous crystalline
compound
respect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022547697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512763A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/016414 external-priority patent/WO2021158663A1/en
Publication of JP2023512763A publication Critical patent/JP2023512763A/ja
Publication of JP2023512763A5 publication Critical patent/JP2023512763A5/ja
Priority to JP2025093285A priority Critical patent/JP2025120268A/ja
Pending legal-status Critical Current

Links

JP2022547697A 2020-02-06 2021-02-03 眼疾患の処置のための組成物 Pending JP2023512763A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093285A JP2025120268A (ja) 2020-02-06 2025-06-04 眼疾患の処置のための組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062971002P 2020-02-06 2020-02-06
US62/971,002 2020-02-06
US202063010212P 2020-04-15 2020-04-15
US63/010,212 2020-04-15
PCT/US2021/016414 WO2021158663A1 (en) 2020-02-06 2021-02-03 Compositions for treatment of ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093285A Division JP2025120268A (ja) 2020-02-06 2025-06-04 眼疾患の処置のための組成物

Publications (2)

Publication Number Publication Date
JP2023512763A JP2023512763A (ja) 2023-03-29
JP2023512763A5 true JP2023512763A5 (cg-RX-API-DMAC10.html) 2024-02-09

Family

ID=77200537

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547697A Pending JP2023512763A (ja) 2020-02-06 2021-02-03 眼疾患の処置のための組成物
JP2025093285A Pending JP2025120268A (ja) 2020-02-06 2025-06-04 眼疾患の処置のための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093285A Pending JP2025120268A (ja) 2020-02-06 2025-06-04 眼疾患の処置のための組成物

Country Status (11)

Country Link
US (2) US11873279B2 (cg-RX-API-DMAC10.html)
EP (1) EP4100406A4 (cg-RX-API-DMAC10.html)
JP (2) JP2023512763A (cg-RX-API-DMAC10.html)
KR (1) KR20220143685A (cg-RX-API-DMAC10.html)
CN (1) CN115103842A (cg-RX-API-DMAC10.html)
AU (1) AU2021217358A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022015579A2 (cg-RX-API-DMAC10.html)
CA (1) CA3168810A1 (cg-RX-API-DMAC10.html)
IL (1) IL294873A (cg-RX-API-DMAC10.html)
MX (1) MX2022009677A (cg-RX-API-DMAC10.html)
WO (1) WO2021158663A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7664239B2 (ja) * 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
BR112023022705A2 (pt) 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
CN117295520A (zh) * 2021-04-30 2023-12-26 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
WO2025137005A1 (en) * 2023-12-20 2025-06-26 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases
AU2024405327A1 (en) * 2023-12-20 2026-07-02 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
CZ20032350A3 (en) 2001-02-02 2004-03-17 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
PL2424530T3 (pl) 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
AR080888A1 (es) 2010-04-12 2012-05-16 R Tech Ueno Ltd Uso de un derivado de acido graso para producir una composicion oftalmica
ES2813383T3 (es) 2013-12-19 2021-03-23 Tassos Georgiou Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso
RU2016133980A (ru) * 2014-01-23 2018-03-01 Экебиа Терапьютикс, Инк. Композиции и способы для лечения заболеваний глаз
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
JP2018522942A (ja) 2015-05-29 2018-08-16 エッジ セラピューティクス インコーポレイテッド 視力障害を低減するための組成物及び方法
JP6745594B2 (ja) * 2015-11-26 2020-08-26 持田製薬株式会社 ピラゾール誘導体の塩の結晶
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) * 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
US10905770B2 (en) 2017-07-17 2021-02-02 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
KR102771305B1 (ko) * 2017-09-15 2025-02-24 모찌다 세이야쿠 가부시끼가이샤 테트라히드로나프틸우레아 유도체의 결정
WO2019210194A1 (en) 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
JP7664239B2 (ja) 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases

Similar Documents

Publication Publication Date Title
US10918656B2 (en) Therapeutic agent for dry eye characterized by being applied to eye of dry eye patient wearing soft contact lens
JP2009029828A (ja) Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
EA016227B1 (ru) Способ лечения офтальмологических неоваскулярных расстройств
JP5875585B2 (ja) 緑内障および高眼圧症の処置のためのアデノシンa1アゴニスト
CN115103842A (zh) 用于治疗眼部疾病的组合物
US8501708B2 (en) Adenosine compounds and their use thereof
JP2010514733A (ja) 高眼圧症の治療のためのイソソルビドモノニトレート誘導体
WO2019124489A1 (ja) セペタプロストとep2アゴニストとの組み合わせ医薬
JP2022520410A5 (cg-RX-API-DMAC10.html)
CN102933593A (zh) 使用n6-环戊基腺苷(cpa)、cpa衍生物或其前药降低人眼内压的方法
US20240182428A1 (en) Prodrug of celecoxib, preparation method therefor and application thereof
WO2022034909A1 (ja) セペタプロストを含有する医薬製剤
TW201309343A (zh) 經改善親水性藥物之藥物移行性之水性組成物
US5055480A (en) Topically active ocular gem-diacylthiadiazole sulfonamide carbonic anhydrase inhibitors
CN111479567B (zh) 包含FP激动剂和β-阻断剂的青光眼的治疗剂
JP2024516829A5 (cg-RX-API-DMAC10.html)
JP2012250947A (ja) アデノシン誘導体とβ受容体遮断薬の組合せ剤
JP2012250953A (ja) アデノシン誘導体とα2受容体作動薬の組合せ剤
TWI917308B (zh) 歐米德尼培(Omidenepag)之組合
JP2012250950A (ja) アデノシン誘導体とプロスタグランジン類の組合せ剤
TW202539693A (zh) 用以使罹患青光眼或高眼壓症之患者於夜間睡眠時之眼壓下降之含有賽佩普斯特(Sepetaprost)之點眼液
JP2012250952A (ja) アデノシン誘導体とRhoキナーゼ阻害剤の組合せ剤
JP2012250948A (ja) アデノシン誘導体と炭酸脱水酵素阻害剤の組合せ剤